ClinConnect ClinConnect Logo
Search / Trial NCT05819801

Effect of Fasting on Patient Outcomes After Wide-Awake, Local Anesthesia-only, No Tourniquet (WALANT) Procedures

Launched by UNIVERSITY OF CALIFORNIA, IRVINE · Apr 6, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying whether eating solid food before a specific type of surgery called a wide-awake local anesthesia-only, no tourniquet (WALANT) procedure can help reduce anxiety and improve overall patient satisfaction. In this study, participants will be randomly divided into two groups: one group will be told to eat before the procedure, and the other will be instructed to fast (not eat). Researchers will then compare levels of anxiety, nausea, and satisfaction during the procedure and at follow-up visits.

To participate in this trial, you should be between the ages of 18 and 74 and scheduled for a WALANT procedure with the lead researcher. However, if you have insulin-dependent diabetes or an allergy to local anesthesia, or if you are unable to attend follow-up visits, you will not be eligible. If you join the study, you can expect to be part of a group that helps understand how eating or fasting might affect your experience during the procedure.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients undergoing wide-awake, local anesthetic-only, no-tourniquet (WALANT) procedures with the lead researcher.
  • Exclusion Criteria:
  • Patients with insulin-dependent diabetes or allergy to local anesthesia, \< 18 years of age, patients unable to follow up.

About University Of California, Irvine

The University of California, Irvine (UCI) is a leading research institution renowned for its commitment to advancing health and medical knowledge through innovative clinical trials. With a robust infrastructure for clinical research, UCI fosters interdisciplinary collaboration among its esteemed faculty and researchers, aiming to translate scientific discoveries into effective therapeutic solutions. The university prioritizes ethical standards and participant safety while addressing critical healthcare challenges across various fields, including cancer, neurology, and public health. UCI's dedication to excellence in research and education positions it as a pivotal contributor to the advancement of clinical science and patient care.

Locations

Orange, California, United States

Patients applied

0 patients applied

Trial Officials

Jesse Kaplan, MD

Principal Investigator

UCI School of Medicine

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported